Structure Therapeutics Inc.’s shares rose after more data on the company’s experimental weight-loss pill showed it’s shaping up to rival new oral treatments from Novo Nordisk A/S and Eli Lilly & Co.
Early in the Covid-19 pandemic, the governor of New Jersey made an unusual admission: He’d run out of COBOL developers. The state’s unemployment insurance systems were written in the 60-year-old ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial. The biotech is planning to launch a late-stage program for the drug later ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results